• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Lupin launches Meloxicam Capsules

expresspharmaDecember 29, 2020

Tag: lupin , Meloxicam Capsules , osteoarthritis , FDA

Lupin announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration (US FDA).

Meloxicam Capsules, 5 mg and 10 mg, is the generic equivalent of Vivlodex Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, and indicated for the management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex) had an annual sales of approximately $11 million in the US (IQVIA MAT October 2020).

Previous:NASSCOM, BIRAC launch ‘JAN-Care’ challenge to scale health tech innovation

Next:SEC asks Bharat Serums to revise phase I/II trial protocols for equine antiserum to treat COVID-19

Related News

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

SCG Cell Therapy Pte Ltd (SCG),announced the signing of a Memorandum of Understanding (MoU) with A*STAR BTI and NATi to advance RNA-based therapeutics manufacturing process development and clinical translation.

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Lupin launches Meloxicam Capsules | Pharmasources.com

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

You may like
More>>

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers

Fully compliance with FDA 21 CFR Part 11 1064nm wavelegth Handhold Raman Spectrometers
Vitamine B12 (FDA)

Vitamine B12 (FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)
Ramantadine( FDA)

Ramantadine( FDA)
Gemfibrozil (FDA)

Gemfibrozil (FDA)
Fluorouracil deoxyriboside( FDA)

Fluorouracil deoxyriboside( FDA)
Ribavirin (FDA)

Ribavirin (FDA)
9,9-Bis(4-aminophenyl) Fluorene (FDA)

9,9-Bis(4-aminophenyl) Fluorene (FDA)
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Meloxicam Capsules

Meloxicam Capsules

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service